Patents by Inventor Andrew Strong

Andrew Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Photodynamic therapy of occult age-related macular degeneration
    Publication number: 20030087889
    Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).
    Type: Application
    Filed: February 6, 2002
    Publication date: May 8, 2003
    Inventors: H. Andrew Strong, Mohammad Azab, Yong Hao, John Miller Koester, Troy Albert Reaves
  • Vision through photodynamic therapy of the eye
    Patent number: 6548542
    Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 15, 2003
    Assignees: QLT Inc., Novartis, A.G.
    Inventors: H. Andrew Strong, Julia Levy, Gustav Huber, Mario Fsadni
  • Method to prevent vision loss
    Publication number: 20020183302
    Abstract: An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
    Type: Application
    Filed: February 6, 2002
    Publication date: December 5, 2002
    Inventors: H. Andrew Strong, Mohammad Azab Ali, Troy Albert Reaves
  • Reduced fluence rate PDT
    Publication number: 20020173832
    Abstract: The invention relates to the use of reduced fluence rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluence rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.
    Type: Application
    Filed: February 6, 2002
    Publication date: November 21, 2002
    Inventor: H. Andrew Strong
  • Vision through photodynamic therapy of the eye
    Patent number: 5910510
    Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: June 8, 1999
    Assignee: QLT Phototherapeutics Inc
    Inventors: H. Andrew Strong, Julia Levy, Gustav Huber, Mario Fsadni
  • Vision through photodynamic therapy of the eye
    Patent number: 5756541
    Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects,
    Type: Grant
    Filed: March 11, 1996
    Date of Patent: May 26, 1998
    Assignee: QLT Phototherapeutics Inc
    Inventors: H. Andrew Strong, Julia Levy, Gustav Huber, Mario Fsadni